A1Control App for Diabetes Management in Youth
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new app called A1Control, designed to help young people manage type 1 diabetes more effectively. Researchers will test the app over 12 weeks to evaluate its performance in everyday home settings. The trial seeks participants aged 10 to 18 who have had type 1 diabetes for over a year and currently use an insulin pump or hybrid closed-loop (HCL) therapy. Participants will use the app to determine if it simplifies and enhances diabetes management. As an unphased trial, this study offers a unique opportunity to contribute to innovative diabetes management solutions.
Will I have to stop taking my current medications?
The trial does not specify whether you need to stop taking your current medications, but since it involves using a diabetes management app, it's likely you can continue your current treatment.
What prior data suggests that the A1Control app is safe for youth?
Research has shown that smartphone apps for managing diabetes, such as A1Control, are generally safe. Studies have found that these apps do not increase episodes of low blood sugar. Although specific safety data for the A1Control app is not available, similar apps have been well-received without an increase in negative effects. This suggests that A1Control is likely safe for young people managing diabetes.12345
Why are researchers excited about this trial?
Researchers are excited about the A1Control app for diabetes management in youth because it offers a modern, tech-driven approach to managing diabetes, unlike traditional methods like insulin therapy and glucose monitoring devices. The app is designed to help young people track their blood sugar levels, dietary intake, and physical activity seamlessly through their smartphones. This integration of technology into daily diabetes management has the potential to make it easier and more engaging for young users to maintain their health, leading to better outcomes and a more personalized healthcare experience.
What evidence suggests that the A1Control app is effective for diabetes management in youth?
Research has shown that the A1Control app, which all participants in this trial will use, may help young people manage their diabetes. One study found that users of the app improved their blood sugar control by 15.8%, compared to a 10.4% improvement in those who didn't use the app. This suggests the app might enhance blood sugar levels more effectively than standard care alone. Other research indicates that regularly using similar diabetes management apps is linked to better blood sugar control in everyday life. However, some studies have not shown a significant drop in blood sugar levels, so results can vary.12367
Are You a Good Fit for This Trial?
This trial is for young people aged 10-18 with type 1 diabetes for over a year, who are already using an insulin pump or hybrid closed-loop therapy for at least six months. It's not suitable for those with significant learning disabilities, pregnant individuals, or those unable to read and write in English.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Youth use a diabetes technology education application in their home environment, with weekly video chat or phone call meetings with research staff
Follow-up
Participants are monitored for safety and effectiveness after treatment, with data collected from diabetes devices and EHR
What Are the Treatments Tested in This Trial?
Interventions
- A1Control
Trial Overview
The study is testing the use of a mobile health (mHealth) app designed to educate youth on diabetes technology. Participants will use this app at home over a period of 12 weeks to see how feasible and helpful it is.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
All participants will perform the same study activities
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ohio State University
Lead Sponsor
Published Research Related to This Trial
Citations
Effectiveness of a new smartphone application on type 1 ...
The primary study endpoint is the HbA1c level after 3 months' follow-up. Secondary outcomes are number of hypoglycaemic events, diabetes treatment satisfaction ...
A1Control App for Diabetes Management in Youth
App users also showed a greater percentage improvement in HbA1c levels (15.8%) compared to non-app users (10.4%), indicating that the app may enhance glycaemic ...
Effect of smartphone apps on glycemic control in young ...
The current pooled data analysis did not reveal a significant reduction in HbA1c in young patients with T1D using smartphone apps and usual care ...
A Mobile App for the Self-Management of Type 1 Diabetes ...
The primary outcome of the study was change in HbA1c (measured in percentage) from baseline to 12 months, between the intervention and control ...
The Effects of Continuous Usage of a Diabetes ...
Our analysis shows that continuous usage of the diabetes management app is associated with better glycemic control in real-world clinical practice.
6.
researchgate.net
researchgate.net/publication/353406624_Simulation_Platform_Development_for_Diabetes_and_Technology_Self-Management(PDF) Simulation Platform Development for Diabetes and ...
Conclusion: A1Control shows potential to increase access and frequency of self-management and technology education. Additional study is needed ...
7.
diabetesjournals.org
diabetesjournals.org/spectrum/article/34/2/139/32959/Beyond-A1C-A-Practical-Approach-to-InterpretingBeyond A1C: A Practical Approach to Interpreting and ...
Understanding and managing glycemic variability is important in children and adolescents. Because A1C provides an incomplete picture of day-to- ...
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.